ClinicalTrials.gg
CompletedNCT03102593Updated Jul 25, 2023

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP

A Phase 2 interventional study of ARGX-113 and Placebo in Primary Immune Thrombocytopenia, sponsored by argenx. Completed at 30 sites in 10 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-07-25.

Sponsored by argenx · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Hungary — 4 open to participants now, 6 under way, 4 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Hungary.

Enrollment
17th of 20
38 · median 76
Started
2017
the only one that year
Phase 2
3 of 20
none open now
Registered
6th of 20
by date
Lead sponsor
4 of 20
argenx

Among the 20 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Hungary, this one is the 17th largest by enrollment, is the only one that started in 2017, is one of 3 in phase 2, and was the 6th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

4 of the 20 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Hungary are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Hungary, or all of them as a file.
02

Study summary

The purpose of the study is to determine safety, efficacy, tolerability and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia.

Read the detailed description

This is a randomized, double-blind, placebo-controlled Phase II study in which approximately 36 patients will be randomized in a 1:1:1 ratio to receive either ARGX-113 Dose A, or ARGX-113 Dose B body weight or placebo in 4 infusions administered 1-week apart in addition to Standard-of-Care (SoC) treatment. Patients aged 18 to 85 years (inclusive) with confirmed primary immune thrombocytopenia (ITP) who have a platelet count ˂ 30 × 109/L and who are receiving oral corticosteroids and/or permitted oral immunosuppressants and/or Thrombopoietin receptor (TPO-R) agonist as SoC which must be maintained on a stable dose and frequency for at least 4 weeks prior to Screening.

The study will include a 2-week Screening, a 3-week Treatment period, and an 21-week follow-up (FU) period. The study is followed by an open label period where patients will be given the option to be treated with ARGX-113 Dose A in cycles of 4 weekly infusions with a minimum of 4 weeks apart. Patients may receive rescue therapy during the study at the discretion the investigator when deemed medically necessary.

03

Conditions studied

  • Primary Immune Thrombocytopenia
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged ≥ 18 to ≤ 85 years.
  2. Must receive SoC treatment for ITP that has been stable in dose and frequency for at least 4 weeks prior to Screening. SoC may include oral and/or permitted oral and/or TPO-R agonist.
  3. Confirmed diagnosis of ITP with blood counts \< 30 × 109/L and who have not experienced major bleeding in the last 4 weeks prior to Screening.

Exclusion criteria

Exclusion Criteria:

  1. Use of anticoagulants, or any drug with antiplatelet effect within 3 weeks prior to Screening.
  2. Patients who have received any blood support or transfusion within 4 weeks prior to Screening.
  3. Use of Intravenous immunoglobulin G (IVIg) or anti-D immunoglobulin treatment within 4 weeks prior to screening.
  4. Use of recombinant thrombopoietin at any time.
  5. Use of rituximab within 6 months prior to Screening. Use of any anti-CD20 other than rituximab at any time is not permitted.
  6. Use of is not permitted within 4 weeks prior to Screening, with the exception of the following oral immunosuppressants: azathioprine, danazol, mycophenolate mofetil, mycophenolate sodium which must have been stable for at least 4 weeks prior to Screening.
  7. Use of any other biological therapy or drug than those previously indicated within 3 months or 5 half-lives of the drug (whichever is longer) prior to Screening.
  8. Received vaccinations within 4 weeks prior to Screening or planned during the study.
  9. At Screening, have laboratory abnormalities
  10. History of any thrombotic or embolic event within 12 months prior to Screening.
  11. Known auto-immune disease other than ITP.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    ARGX-113 Dose A + SoC

    Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo

    Drug: ARGX-113

  • Experimental
    ARGX-113 Dose B +SoC

    Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo

    Drug: ARGX-113

  • Placebo comparator
    Placebo + SoC

    Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo

    Other: Placebo

Interventions

  • ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly

  • OtherPlacebo

    ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly

06

What researchers measure

Primary outcomes

  1. Incidence and severity of serious adverse events (SAEs).

    Changes from Baseline in vital signs, electrocardiogram parameters (ECGs), physical examination abnormalities and clinical laboratory assessments.

    Time frame: After the first administration of Investigational Medicinal Product day 1 to 30 days of a patient's last visit.

Secondary outcomes

  1. Frequency and proportion of patients with initial response

    Mean change from Baseline in platelet counts

    Time frame: Over the study period (up to 13 weeks).

07

Study locations

30 sites
  • Vienna
    Vienna, Austria
  • Wien
    Wien, Austria
  • Leuven
    Leuven, Belgium
  • Mont-Godinne
    Namur, Belgium
  • Brno
    Brno, Czechia
  • Praha
    Praha, Czechia
  • Bordeaux
    Bordeaux, France
  • Grenoble
    Grenoble, France
  • Paris
    Paris, France
  • Berlin
    Berlin, Germany
  • Hanover
    Hanover, Germany
  • Tubingen
    Tubingen, Germany
  • Budapest
    Budapest, Hungary
  • Debrecen
    Debrecen, Hungary
  • Gyula
    Gyula, Hungary
  • Kaposvar
    Kaposvar, Hungary
  • Nyiregyhaza
    Nyiregyhaza, Hungary
  • Pecs
    Pecs, Hungary
  • Lublin
    Lublin, Poland
  • Opole
    Opole, Poland
  • Wroclaw
    Wroclaw, Poland
  • A Coruna
    A Coruña, Spain
  • Barcelona
    Barcelona, Spain
  • Madrid
    Madrid, Spain
  • Valencia
    Valencia, Spain
  • Dnipro
    Dnipro, Ukraine
  • Ivano-Frankivsk
    Ivano-Frankivsk, Ukraine
  • Nikolaev
    Nikolaev, Ukraine
  • Uzhgorod
    Uzhgorod, Ukraine
  • London
    London, United Kingdom
08

References and documents

Publications

  • Newland AC, Sanchez-Gonzalez B, Rejto L, Egyed M, Romanyuk N, Godar M, Verschueren K, Gandini D, Ulrichts P, Beauchamp J, Dreier T, Ward ES, Michel M, Liebman HA, de Haard H, Leupin N, Kuter DJ. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol. 2020 Feb;95(2):178-187. doi: 10.1002/ajh.25680. Epub 2019 Dec 10. PubMed 31821591 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Apr 2019, 24 months.

Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2017
First posted
Apr 6, 2017
StartActual
Mar 13, 2017
Primary completionActual
Apr 9, 2019
CompletionActual
Apr 9, 2019
Last update
Jul 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03102593
Lead sponsor
argenx
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
Apr 6, 2017
Start date
Mar 13, 2017
Primary completion
Apr 9, 2019
Completion
Apr 9, 2019
Last update
Jul 25, 2023

Study contacts

Adrian Newland
study chair · Barts Hospital, Cancer Centre in London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion